What are the treatment options for a 66-year-old man with a prostate biopsy showing Gleason 6 (3+3) in six of fourteen cores and Gleason 7 (3+4) in one of fourteen cores, and a prostate-specific antigen of 5.2 ng/mL?

Treatment Options for Gleason 6 and 7 (3+4) Prostate Cancer

This 66-year-old man with intermediate-risk prostate cancer (PSA 5.2, Gleason 7 [3+4] present) should be offered radical prostatectomy, external beam radiotherapy with short-term androgen deprivation therapy (4-6 months), or brachytherapy boost combined with radiotherapy plus short-term ADT, with the understanding that the presence of any Gleason 7 disease—even in a single core—upgrades him from low-risk to intermediate-risk and necessitates definitive treatment rather than active surveillance. 1

Risk Stratification

This patient's disease profile places him in the intermediate-risk category based on:

• PSA 5.2 ng/mL (favorable, <10)
• Gleason 7 (3+4) in 1/14 cores (unfavorable pattern)
• Gleason 6 in 6/14 cores (43% core involvement)
• Age 66 with presumed >10 year life expectancy

The critical distinction here is that even a single core of Gleason 7 disease excludes this patient from low-risk classification and makes active surveillance inappropriate as a primary strategy 1, 2. The 2024 EAU guidelines specifically state that patients with Gleason 7 disease require definitive treatment, not observation 1.

Definitive Treatment Options

1. Radical Prostatectomy

Offer radical prostatectomy as first-line treatment for patients with life expectancy >10 years 1. This provides:

• Complete pathological staging
• Ability to assess true extent of disease (important given 82-91% of Gleason 6 on biopsy upgrades to ≥7 at surgery) 3
• Option for nerve-sparing if low risk of extracapsular extension on his side without Gleason 7
• Salvage radiotherapy option if PSA rises postoperatively

Critical caveat: Research shows that 82.9% of patients with Gleason 6 on biopsy who undergo immediate prostatectomy have Gleason ≥7 disease on final pathology 3. Given this patient already has Gleason 7 on biopsy, expect potential upstaging.

The surgery can be safely delayed up to 3 months if needed for patient preparation 1.

2. External Beam Radiotherapy with Androgen Deprivation

Offer IMRT/VMAT with image guidance (76-78 Gy) combined with short-term ADT for 4-6 months 1. Alternative acceptable regimens include:

• Moderate hypofractionation: 60 Gy in 20 fractions over 4 weeks, or 70 Gy in 28 fractions over 6 weeks 1
• Ultrahypofractionation: 36.25 Gy in 5 fractions or 42.7 Gy in 7 fractions on alternate days 1

The addition of short-term ADT (4-6 months) is mandatory for intermediate-risk disease treated with radiotherapy 1, 2. This combination improves outcomes compared to radiotherapy alone.

Evidence supporting radiotherapy: A 2015 comparative study showed superior 5-year PSA relapse-free survival for radiotherapy versus prostatectomy alone (82.6% vs 55.4%, p<0.0001) in Gleason 7 patients 4, though this may reflect inadequate use of adjuvant radiotherapy in the surgery group.

3. Brachytherapy-Based Approaches

For patients with good urinary function:

Option A: LDR brachytherapy boost + IMRT/VMAT with short-term ADT (4-6 months) 1

Option B: HDR brachytherapy boost + IMRT/VMAT with short-term ADT (4-6 months) 1

Option C: LDR brachytherapy monotherapy may be considered for "favorable" intermediate-risk (Gleason 7 with PSA <10) 5, 1, though this patient's 43% core involvement may push toward combination therapy.

The 2017 ASCO/CCO guidelines support brachytherapy boost for intermediate-risk disease, showing improved outcomes over external beam alone 5.

Why Active Surveillance is NOT Appropriate

Despite the predominance of Gleason 6 disease (6/14 cores), active surveillance should not be offered because:

1. Any Gleason 7 disease excludes low-risk classification 1, 2
2. The NCCN 2010 guidelines note that Gleason 7 on biopsy triggers intervention in active surveillance protocols 6
3. Even favorable Gleason 3+4=7 in selected patients with comorbidity might warrant surveillance 7, but this requires very careful selection and is not standard practice
4. Research shows 90.6% of patients with Gleason 6 who progress on active surveillance to surgery have Gleason ≥7 on final pathology 3

Staging Workup Required

Before treatment, this patient needs:

• No routine pelvic imaging (PSA <10 and not high-risk) 8
• No bone scan (Gleason not >4+3 and PSA <15) 8, 9
• Digital rectal examination for clinical T staging 2
• Consider multiparametric MRI if not already done (though biopsy already performed) 2

Treatment Selection Algorithm

Choose radical prostatectomy if:

• Patient prefers single definitive intervention
• Acceptable surgical risk
• Values knowing complete pathological staging
• Willing to accept 80% erectile dysfunction and 49% urinary leakage risks 8

Choose radiotherapy + ADT if:

• Patient wishes to avoid surgery
• Comorbidities increase surgical risk
• Patient accepts 4-6 months of hormonal therapy side effects
• Research suggests potentially superior biochemical control 4

Choose brachytherapy-based therapy if:

• Good baseline urinary function (critical requirement)
• Desires potentially superior local control
• Acceptable candidate for combination therapy

Critical Pitfalls to Avoid

1. Do not offer active surveillance based on the predominance of Gleason 6—the single Gleason 7 core mandates treatment
2. Do not perform radiotherapy without ADT in intermediate-risk disease—the combination is essential 1
3. Do not assume Gleason 6 on biopsy means Gleason 6 disease—expect upstaging in >80% 3
4. Do not delay treatment indefinitely—while 3-month delays are safe, prolonged observation is not appropriate 1

Gleason 3+4 vs 4+3 Distinction

This patient has Gleason 3+4=7, which carries better prognosis than 4+3=7 10. The primary pattern being 3 (not 4) is an independent predictor of better outcomes regardless of core involvement 10. This favorable biology supports all three definitive treatment options with good expected outcomes.